These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
58 related articles for article (PubMed ID: 1000028)
1. Plasma prolactin response to L-dopa TRH and metaclopramide in thyrotoxicosis. Delitala G; Masala A; Alagna S; Devilla L Biomedicine; 1976 Jul; 25(5):173-6. PubMed ID: 1000028 [TBL] [Abstract][Full Text] [Related]
2. Dose-dependency and reproducibility of the prolactin response to metoclopramide. Kitaoka M; Takebe K; Kobayashi M; Nakazono M; Kudo M Horm Metab Res; 1980 Apr; 12(4):155-8. PubMed ID: 6771199 [TBL] [Abstract][Full Text] [Related]
3. Decreased prolactin responsiveness to thyrotrophin-releasing hormone and metoclopramide in hyperthyroidism. Röjdmark S; Carlsson A Acta Endocrinol (Copenh); 1985 Oct; 110(2):221-6. PubMed ID: 2998132 [TBL] [Abstract][Full Text] [Related]
4. Metaclopramide and prolactin secretion in man: effects of pretreatment with L-dopa and 2-bromo-alpha-ergocryptine (CB-154). Delitala G; Masala A; Alagna S; Devilla L IRCS J Med Sci; 1975 Jun; 3(6):274. PubMed ID: 1165172 [No Abstract] [Full Text] [Related]
5. Effects of antidepressant treatment on thyrotropin-releasing hormone stimulation, growth hormone response to L-DOPA, and dexamethasone suppression tests in major depressive patients. Esel E; Kartalci S; Tutus A; Turan T; Sofuoglu S Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):303-9. PubMed ID: 14751427 [TBL] [Abstract][Full Text] [Related]
6. Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients. Lissoni P; Malugani F; Casu M; Bukovec R; Egardi R; Bordin V; Fumagalli E; Mengo S; Gardani G Neuro Endocrinol Lett; 2002 Feb; 23(1):61-3. PubMed ID: 11880864 [TBL] [Abstract][Full Text] [Related]
8. Paradoxical stimulation of prolactin secretion by L-dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemia. Lissoni P; Mandalà M; Rovelli F; Casu M; Rocco F; Tancini G; Scardino E Eur Urol; 2000 May; 37(5):569-72. PubMed ID: 10765095 [TBL] [Abstract][Full Text] [Related]
9. Abnormal growth hormone responsiveness to stimuli in women with active celiac sprue. Peracchi M; Molteni N; Cantalamessa L; Bardella MT; Peracchi G; Orsatti A; Faggioli P; Bianchi PA Am J Gastroenterol; 1992 May; 87(5):580-3. PubMed ID: 1595643 [TBL] [Abstract][Full Text] [Related]
10. [The effects of l-dopa administration on the prolactin levels in short-stature subjects]. Saggese G; Cesaretti G; Carlotti C; Cioni C; Bracaloni C Minerva Pediatr; 1992 Mar; 44(3):73-8. PubMed ID: 1518496 [TBL] [Abstract][Full Text] [Related]
11. Pyridoxine and depression: neuroendocrine aspects. Casacchia M; Boni B; Meco G Acta Vitaminol Enzymol; 1982; 4(1-2):55-8. PubMed ID: 6812398 [TBL] [Abstract][Full Text] [Related]
12. [Reevaluation of the I-dopa test in acromegaly: anatomo-clinical and prognostic correlations]. De Marinis L; Mancini A; Zuppi P; Fiumara C; Iacona T; Conte G; Fabrizi ML; Valle D; Anile C; Maira G Minerva Chir; 1993 Nov; 48(21-22):1337-40. PubMed ID: 8152567 [TBL] [Abstract][Full Text] [Related]
13. L-DOPA attenuates prolactin secretion in response to isolation stress in Holstein steers. Kasuya E; Yayou K; Sutoh M Anim Sci J; 2013 Jul; 84(7):562-8. PubMed ID: 23607456 [TBL] [Abstract][Full Text] [Related]
14. [Possible mechanisms of the interaction between gonadotropins and prolactin in an experimental hyperprolactinemia model]. Tresguerres JA; Esquifino AI Acta Physiol Lat Am; 1983; 33(3):257-74. PubMed ID: 6424409 [TBL] [Abstract][Full Text] [Related]
15. [Hyperthyroidism and subjects hyperresponding to thyrotropin. Importance of simultaneous thyrotropin and prolactin determination following administration of thyroid-releasing hormone]. Schlienger JL; De Laharpe F; Reville P; Stephan F Sem Hop; 1980 May 8-15; 56(17-18):827-31. PubMed ID: 6248964 [TBL] [Abstract][Full Text] [Related]
16. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture. Ishibashi M; Yamaji T J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273 [TBL] [Abstract][Full Text] [Related]
17. Human prolactin and thyrotropin concentrations in the serums of normal and hypopituitary children before and after the administration of synthetic thyrotropin-releasing hormone. Foley TP; Jacobs LS; Hoffman W; Daughaday WH; Blizzard RM J Clin Invest; 1972 Aug; 51(8):2143-50. PubMed ID: 4626583 [TBL] [Abstract][Full Text] [Related]
18. Hypothalamic dysfunction in Parkinson's disease patients. Otake K; Oiso Y; Mitsuma T; Hirooka Y; Adachi K Acta Med Hung; 1994; 50(1-2):3-13. PubMed ID: 7638039 [TBL] [Abstract][Full Text] [Related]
19. Effect of metoclopramide and L-dopa on a single dose metyrapone test in normal men. Matsuki M; Nishida S; Nagase Y; Horino M; Endoh M; Kakita K; Tenku A; Oyama H Horm Metab Res; 1983 Oct; 15(10):519-21. PubMed ID: 6315558 [No Abstract] [Full Text] [Related]
20. The effect of cysteamine, cystamine, and the structurally related compounds taurine, N-acetyl-cysteine, and D-penicillamine on plasma prolactin levels in normal and estrogen-primed hyperprolactinemic rats. Scott JS; Lakin CA; Oliver JR Endocrinology; 1987 Aug; 121(2):812-8. PubMed ID: 3109888 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]